Atlanta Consulting Group Advisors LLC Has $315,000 Holdings in Boston Scientific Co. (NYSE:BSX)

Atlanta Consulting Group Advisors LLC boosted its stake in Boston Scientific Co. (NYSE:BSX) by 17.4% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,757 shares of the medical equipment provider’s stock after buying an additional 557 shares during the quarter. Atlanta Consulting Group Advisors LLC’s holdings in Boston Scientific were worth $315,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Schear Investment Advisers LLC grew its holdings in shares of Boston Scientific by 9.6% in the 3rd quarter. Schear Investment Advisers LLC now owns 19,770 shares of the medical equipment provider’s stock worth $1,657,000 after purchasing an additional 1,727 shares during the last quarter. RIA Advisory Group LLC bought a new position in Boston Scientific during the 3rd quarter valued at about $265,000. Natixis Advisors LLC boosted its position in Boston Scientific by 5.5% in the third quarter. Natixis Advisors LLC now owns 1,845,805 shares of the medical equipment provider’s stock valued at $154,678,000 after buying an additional 96,451 shares in the last quarter. Mizuho Markets Americas LLC bought a new stake in Boston Scientific during the third quarter worth about $739,000. Finally, Empowered Funds LLC increased its holdings in shares of Boston Scientific by 7.9% during the third quarter. Empowered Funds LLC now owns 23,413 shares of the medical equipment provider’s stock worth $1,962,000 after buying an additional 1,715 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific Price Performance

BSX opened at $86.99 on Monday. The company has a fifty day simple moving average of $85.26 and a 200 day simple moving average of $79.59. The company has a quick ratio of 1.02, a current ratio of 1.48 and a debt-to-equity ratio of 0.44. The stock has a market cap of $128.21 billion, a P/E ratio of 71.89, a P/E/G ratio of 2.56 and a beta of 0.79. Boston Scientific Co. has a 12 month low of $53.56 and a 12 month high of $89.30.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.59 by $0.04. The business had revenue of $4.21 billion for the quarter, compared to analysts’ expectations of $4.04 billion. Boston Scientific had a return on equity of 17.23% and a net margin of 11.26%. Boston Scientific’s revenue for the quarter was up 19.3% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.50 EPS. On average, research analysts expect that Boston Scientific Co. will post 2.46 EPS for the current year.

Insider Buying and Selling

In related news, EVP Joseph Michael Fitzgerald sold 132,527 shares of the stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $85.00, for a total transaction of $11,264,795.00. Following the completion of the transaction, the executive vice president now directly owns 160,467 shares in the company, valued at approximately $13,639,695. This trade represents a 45.23 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Wendy Carruthers sold 6,983 shares of the business’s stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $83.86, for a total value of $585,594.38. Following the completion of the sale, the executive vice president now owns 34,748 shares in the company, valued at $2,913,967.28. The trade was a 16.73 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 309,270 shares of company stock worth $26,196,718 over the last ninety days. Company insiders own 0.50% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently commented on BSX shares. JPMorgan Chase & Co. increased their price target on Boston Scientific from $82.00 to $85.00 and gave the stock an “overweight” rating in a research report on Thursday, July 25th. Morgan Stanley increased their target price on Boston Scientific from $92.00 to $100.00 and gave the stock an “overweight” rating in a report on Thursday, October 24th. Royal Bank of Canada lifted their price target on Boston Scientific from $95.00 to $98.00 and gave the company an “outperform” rating in a report on Thursday, October 24th. BTIG Research increased their price objective on shares of Boston Scientific from $84.00 to $93.00 and gave the stock a “buy” rating in a report on Monday, October 14th. Finally, Bank of America boosted their target price on shares of Boston Scientific from $90.00 to $100.00 and gave the stock a “buy” rating in a research note on Tuesday, October 22nd. Four investment analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $93.39.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.